IPLA

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

iPLA, also known as N-isopropyllysergamide, as well as lysergic acid isopropylamide (LAiP), is a serotonin receptor modulator and possible serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethyl groups have been replaced with an N-isopropyl group. In an early study, iPLA showed about 22.2% of the antiserotonergic activity of LSD in the isolated rat uterus. The drug is known to bind with high affinity (K i ) to the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 1A receptors. It is a potent agonist of the serotonin 5-HT 2A receptor. iPLA fully substituted for LSD in rodent drug discrimination tests with a potency of about half that of LSD itself, findings which suggest that iPLA may have psychedelic effects in humans. iPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s. It is not a controlled substance in Canada as of 2025.

iPLA, also known as N-isopropyllysergamide, as well as lysergic acid isopropylamide (LAiP), is a serotonin receptor modulator and possible serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethyl groups have been replaced with an N-isopropyl group. In an early study, iPLA showed about 22.2% of the antiserotonergic activity of LSD in the isolated rat uterus. The drug is known to bind with high affinity (K i ) to the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 1A receptors. It is a potent agonist of the serotonin 5-HT 2A receptor. iPLA fully substituted for LSD in rodent drug discrimination tests with a potency of about half that of LSD itself, findings which suggest that iPLA may have psychedelic effects in humans. iPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s. It is not a controlled substance in Canada as of 2025.

See also

Substituted lysergamide Lysergic acid propylamide MiPLA (lysergic acid methylisopropylamide) EiPLA (lysergic acid ethylisopropylamide) DiPLA (lysergic acid diisopropylamide) Lysergic acid tert-butylamide (LAtB)

References

External links

iPLA - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368387963 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.